COMMUNIQUÉS West-GlobeNewswire

SEED Therapeutics Doses First Patient in Phase 1 Trial of ST-01156, a Molecular Glue Degrader Targeting RBM39
09/01/2026
First-in-human study evaluates safety, pharmacokinetics, biomarker analyses, target engagement, and anti-tumor activity in patients with advanced solid tumors ST-01156 has received U.S. FDA Orphan Drug Designation and [...]
Angels My Way Home Care Celebrates 15th 5-Star Google Review, Reinforcing Role as Best Home Health Care Service in Hamilton, Ontario
09/01/2026
Angels My Way Home Care continues to set the standard for excellence in home health care services with its latest milestone. Hamilton, Ontario, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Angels My Way Home Care , a leading [...]
Fortrea Announces Updated Presentation Time at Upcoming J.P. Morgan Healthcare Conference
09/01/2026
DURHAM, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced an updated presentation time of 11:15 am PST on Tuesday, January 13, 2026, [...]
Disclosure of notification received from BNP Paribas
09/01/2026
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 09 January 2026 – 5:40 PM CET Disclosure of notification received from BNP Paribas Pursuant to the Belgian law of 2 May 2007 regarding the disclosure [...]
Bright Minds Biosciences Announces Closing of US$175 Million Public Offering
09/01/2026
NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“ Bright Minds ” or the “ Company ”) today closed its recently announced public offering of 1,945,000 common shares [...]
Virbac : Déclaration d'actions et de droits de vote 12/2025
09/01/2026
DECLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
Virbac : Declaration of the number of shares and voting rights 12/2025
09/01/2026
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
uniQure Announces Type A Meeting Scheduled with FDA
09/01/2026
LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced a [...]
Bruder Consulting & Venture Group to become Dark Horse Consulting Regenerative Medicine
09/01/2026
WALNUT CREEK, Calif. and NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group (“DHCG” or “the Group”), a leader in strategic and operational biotherapeutics consulting, is pleased to announce the [...]
Tecan to present at upcoming Investor Conferences
09/01/2026
Männedorf, Switzerland, January 9, 2026 – The Tecan Group (SIX Swiss Exchange: TECN) today announced that it will attend and present at the following investor conferences in the upcoming week: 44 th Annual J.P. Morgan [...]
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies
09/01/2026
Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations (microcystic LMs) remains on track, with topline results anticipated in March 2026; pending [...]
Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones
09/01/2026
-- Q4 2025 preliminary net product revenues from global sales of IMCIVREE ® (setmelanotide) of approximately $57 million for the fourth quarter of 2025, an 11% increase over Q3 2025 -- -- FY 2025 preliminary net product [...]
Peer-reviewed study demonstrates LEON’s FR-JET® modular mixer enables stable high-concentration mRNA-LNPs with enhanced in vivo activity
09/01/2026
PLANEGG, Germany and MUNICH, Jan. 09, 2026 (GLOBE NEWSWIRE) -- A new study published in Pharmaceutics ( https://doi.org/10.3390/pharmaceutics18010050 ) shows that LEON’s FR-JET ® modular mixer addresses key [...]
Flare Therapeutics Appoints Stephen L. Eck, M.D., Ph.D., as Chief Medical Officer
09/01/2026
CAMBRIDGE, Mass., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other [...]
Elutia to Present at Global BioInnovation Forum on NXT-41x Biomatrix Program for Plastic and Reconstructive Surgery
09/01/2026
Company to present Tuesday, January 13 th at 10:00 a.m. PT / 1:00 p.m. ET GAITHERSBURG, Md., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix [...]
NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities
09/01/2026
-- EMA approval decision for obicetrapib and obicetrapib/ezetimibe fixed dose combo expected in 2H26 -- -- Phase 3 PREVAIL CVOT overall event rate tracking in line with observed rate in BROADWAY -- -- First patient [...]
Medicines360 Acquires Global Licensing Rights to Innovative Maternal Health Technologies for Risk Identification and Management Throughout Pregnancy
09/01/2026
Licensing of scientific discoveries from University of Cambridge and University of Edinburgh is aimed to speed translation and access to life-saving diagnostics for women worldwide. SAN FRANCISCO, Jan. 09, 2026 (GLOBE [...]
Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor
09/01/2026
Agreement expands Madrigal’s pipeline and strengthens its leadership in pioneering MASH therapies DGAT-2 inhibition represents a complementary mechanism of action with Rezdiffra ® (resmetirom) for potential additive [...]
Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook
09/01/2026
Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential opportunity for a single [...]

Pages